Comparison of radiotherapy with and without razoxane (icrf 159) in the treatment of soft tissue sarcomas
- 1 January 1978
- Vol. 41 (1) , 100-107
- https://doi.org/10.1002/1097-0142(197801)41:1<100::aid-cncr2820410115>3.0.co;2-p
Abstract
Comparison of the recurrence rates of soft tissue sarcomas treated by radiotherapy (14 patients) or radiotherapy and synchronous administration of razoxane (19 patients) has shown a statistically significant benefit for those patients treated by the combination. No increase in tissue reactions or adverse side-effects (apart from a readily reversible leukopenia) was observed. The implication is that razoxane acts as a well tolerated adjuvant for radiotherapy.This publication has 15 references indexed in Scilit:
- Modification of the radiocurability of a syngeneic murine squamous carcinoma by its site of growth, by electron-affinic drugs, and by ICRF 159The British Journal of Radiology, 1976
- The effect of (±) 1,2-bis(3,5-dioxopiperazin-1-yl) propane (ICRF 159) on liver metastases from a hamster lymphomaPublished by Elsevier ,1975
- Soft tissue sarcomas of the extremities: Their natural history, treatment, and radiation sensitivityJournal of Surgical Oncology, 1975
- Strahlentherapie und ICRF 159 (NSC 129943) in der Behandlung inoperabler WeichteilsarkomeDeutsche Medizinische Wochenschrift (1946), 1974
- Clinical use of radiation sensitizing agentsCancer Treatment Reviews, 1974
- Combined treatment of the Walker tumour with radiotherapy and ICRF 159Zeitschrift für Krebsforschung und Klinische Onkologie, 1974
- Metastases and the Normalization of Tumour Blood Vessels by ICRF 159: A New Type of Drug ActionBMJ, 1972
- SPLIT-DOSE RADIOTHERAPY FOR RADIORESISTANT BONE AND SOFT TISSUE SARCOMA: TEN YEARS' EXPERIENCEAmerican Journal of Roentgenology, 1972
- Inhibition of Metastatic Spread by I.C.R.F. 159: Selective Deletion of a Malignant CharacteristicBMJ, 1970
- Mode of Action of the Cytostatic Agent ‘ICRF 159’Nature, 1970